Chi‐Un Pae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chi‐Un Pae has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jeong‐Ho Chae
Department of Psychiatry, St. Mary's Hospital, The Catholic University of Korea, College of Medicine
5 shared publicationsKwang‐Soo Kim
Department of Psychiatry, St. Mary's Hospital, The Catholic University of Korea, College of Medicine
5 shared publicationsWon‐Myong Bahk
Department of Psychiatry, St. Mary's Hospital, The Catholic University of Korea, College of Medicine
5 shared publicationsTae‐Youn Jun
Department of Psychiatry, St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea
4 shared publicationsHoon Han
Department of Microbiology and Immunology, The Catholic University of Korea, College of Medicine, Seoul, Korea
3 shared publicationsChul‐ Lee
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Kangnam St Mary' Hospital, 505 Banpo‐Dong, Seocho‐Gu, Seoul 137‐701, Korea
1 shared publication
Latest Publications
- 8 January 2003
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 57 (1) , 31-35
Tumor necrosis factor‐β gene polymorphism may not be associated with major depressive disorder in the Korean population
Tumor necrosis factor (TNF)‐β has been implicated in the regulation of immune system. Alterations of the immune system in patients with major depressive disorder (MDD) have been also proposed to date. The present study was undertaken to investigate whether TNF‐β gene polymorphism is associated with MDD in the Korean population. Ninety‐five patients with MDD who met the criteria of DSM‐IV and 202 gender‐ and age‐matched unrelated volunteers participated in the study. Genotyping for TNF‐β gene was performed by a polymerase chain reaction‐restriction fragment length polymorphism method. The genotype and allele distribution in patients with MDD was similar to that of the controls. This study suggests that the TNF‐β gene polymorphism does not confer a susceptibility to MDD in the Korean population. A larger scaled study to examine different races is necessary to determine a role in the pathogenesis of MDD.
- 8 January 2003
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 57 (1) , 31-35
Tumor necrosis factor‐β gene polymorphism may not be associated with major depressive disorder in the Korean population
Tumor necrosis factor (TNF)‐β has been implicated in the regulation of immune system. Alterations of the immune system in patients with major depressive disorder (MDD) have been also proposed to date. The present study was undertaken to investigate whether TNF‐β gene polymorphism is associated with MDD in the Korean population. Ninety‐five patients with MDD who met the criteria of DSM‐IV and 202 gender‐ and age‐matched unrelated volunteers participated in the study. Genotyping for TNF‐β gene was performed by a polymerase chain reaction‐restriction fragment length polymorphism method. The genotype and allele distribution in patients with MDD was similar to that of the controls. This study suggests that the TNF‐β gene polymorphism does not confer a susceptibility to MDD in the Korean population. A larger scaled study to examine different races is necessary to determine a role in the pathogenesis of MDD.
- 24 September 2002
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 17 (7) , 341-344
Effects of mirtazapine in patients with post‐traumatic stress disorder in Korea: a pilot study
This study was aimed at testing the efficacy and tolerability of mirtazapine in the treatment of Korean patients with chronic post‐traumatic stress disorder (PTSD). Mirtazapine was administered for 8 weeks using a flexible‐dose regime in 15 Korean patients with PTSD based on the DSM‐IV criteria. We evaluated the patients at baseline and at weeks 4 and 8 after treatment with the interviewer‐administered structured interview for PTSD (SIP), short PTSD rating interview (SPRINT), impact of event scale‐revised (IES‐R) and the Montgomery Åsberg depression rating scale (MADRS). Scores on the SIP, SPRINT, IES‐R and MADRS had significantly reduced after 8 weeks treatment. In this pilot study, mirtazapine was found to be effective and well tolerated in the treatment of patients with PTSD. This calls for further evaluation of the effect of this drug on subjects with PTSD with randomized placebo‐controlled studies. Copyright © 2002 John Wiley & Sons, Ltd.
- 24 September 2002
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 17 (7) , 341-344
Effects of mirtazapine in patients with post‐traumatic stress disorder in Korea: a pilot study
This study was aimed at testing the efficacy and tolerability of mirtazapine in the treatment of Korean patients with chronic post‐traumatic stress disorder (PTSD). Mirtazapine was administered for 8 weeks using a flexible‐dose regime in 15 Korean patients with PTSD based on the DSM‐IV criteria. We evaluated the patients at baseline and at weeks 4 and 8 after treatment with the interviewer‐administered structured interview for PTSD (SIP), short PTSD rating interview (SPRINT), impact of event scale‐revised (IES‐R) and the Montgomery Åsberg depression rating scale (MADRS). Scores on the SIP, SPRINT, IES‐R and MADRS had significantly reduced after 8 weeks treatment. In this pilot study, mirtazapine was found to be effective and well tolerated in the treatment of patients with PTSD. This calls for further evaluation of the effect of this drug on subjects with PTSD with randomized placebo‐controlled studies. Copyright © 2002 John Wiley & Sons, Ltd.
- 1 May 2002
- Published by Elsevier in Psychiatry Research
- Vol. 110 (1) , 19-25
Polymorphism of CTLA-4 gene at position 49 of exon 1 may be associated with schizophrenia in the Korean population
- 1 May 2002
- Published by Elsevier in Psychiatry Research
- Vol. 110 (1) , 19-25
Polymorphism of CTLA-4 gene at position 49 of exon 1 may be associated with schizophrenia in the Korean population
- 28 February 2002
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 56 (2) , 203-205
A case of brief psychosis associated with an arachnoid cyst
Little is known about the arachnoid cyst and there have been few reports of it accompanying psychiatric disturbances. A 57‐year‐old patient was admitted due to sudden headache, auditory hallucination, and delusion of persecution. An arachnoid cyst was found in the anteromedial aspect of middle cranial fossa on his magnetic resonance image. This was his first psychotic episode and he was also negative to other clinical evaluations including endocrine system. His psychotic symtoms were suspected to be induced by the arachnoid cyst and it was well controlled by low‐dose risperidone administration. He left hospital free from psychotic symptoms on 14th hospital day.
- 28 February 2002
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 56 (2) , 203-205
A case of brief psychosis associated with an arachnoid cyst
Little is known about the arachnoid cyst and there have been few reports of it accompanying psychiatric disturbances. A 57‐year‐old patient was admitted due to sudden headache, auditory hallucination, and delusion of persecution. An arachnoid cyst was found in the anteromedial aspect of middle cranial fossa on his magnetic resonance image. This was his first psychotic episode and he was also negative to other clinical evaluations including endocrine system. His psychotic symtoms were suspected to be induced by the arachnoid cyst and it was well controlled by low‐dose risperidone administration. He left hospital free from psychotic symptoms on 14th hospital day.
- 28 February 2002
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 56 (2) , 177-180
Report on IL‐10 gene polymorphism at position –819 for major depression and schizophrenia in Korean population
The present study was carried out to examine the relationship of interleukin (IL)‐10 gene polymorphism at position –819 for major depression and schizophrenia in the Korean population. DNA was extracted from 92 Korean patients with major depression, 141 Korean patients with schizophrenia, and 146 ethnically matched controls. DNA was amplified by a polymerase chain reaction‐based method and digested by MaeIII, and the restriction fragment length polymorphism of two alleles, IL‐10*C and IL‐10*T, were assessed. There were no significant differences in genotype frequencies of IL‐10*T/T, IL‐10*T/C, and IL‐10*C/C as well as allelic frequencies of IL‐10*T and IL‐10*C between patients with major depression and controls in the Korean population. Comparison of genotype and allelic frequencies of IL‐10 gene between patients with schizophrenia and controls were also not significant. The present study suggests that IL‐10 gene polymorphism at position –819 does not confer susceptibility to major depression and schizophrenia, at least in the Korean population. Further systematic studies including various clinical variables would be required.
- 28 February 2002
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 56 (2) , 177-180
Report on IL‐10 gene polymorphism at position –819 for major depression and schizophrenia in Korean population
The present study was carried out to examine the relationship of interleukin (IL)‐10 gene polymorphism at position –819 for major depression and schizophrenia in the Korean population. DNA was extracted from 92 Korean patients with major depression, 141 Korean patients with schizophrenia, and 146 ethnically matched controls. DNA was amplified by a polymerase chain reaction‐based method and digested by MaeIII, and the restriction fragment length polymorphism of two alleles, IL‐10*C and IL‐10*T, were assessed. There were no significant differences in genotype frequencies of IL‐10*T/T, IL‐10*T/C, and IL‐10*C/C as well as allelic frequencies of IL‐10*T and IL‐10*C between patients with major depression and controls in the Korean population. Comparison of genotype and allelic frequencies of IL‐10 gene between patients with schizophrenia and controls were also not significant. The present study suggests that IL‐10 gene polymorphism at position –819 does not confer susceptibility to major depression and schizophrenia, at least in the Korean population. Further systematic studies including various clinical variables would be required.
- Open Access
- 1 October 2001
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 55 (5) , 515-519
An open pilot trial of olanzapine for delirium in the Korean population
This study was performed to assess the efficacy and safety of olanzapine for the treatment of delirium in a Korean population. An open trial of olanzapine was conducted in Korean patients with delirium caused by multiple medicosurgical conditions. All subjects were evaluated by Delirium Rating Scale (DRS), which is known to be one of the most sensitive scales for delirium. In addition, other data for profiles of side‐effects were collected and analyzed. Twenty patients were treated by olanzapine with doses of 5.9 ± 1.5 mg/day. The initial dose was 4.6 ± 0.9 mg/day and maximal dose of olanzapine was 8.8 ± 2.2 mg/day. The average duration of treatment was 6.6 ± 1.7 days and the day of maximal response was 3.8 ± 1.7 treated days. The scores of DRS were significantly improved from 20.0 ± 3.6 at the time of pretreatment to 9.3 ± 4.6 at the post‐treatment. All subjects showed no definite serious side‐effects including anticholinergic and extrapyramidal symptoms. Olanzapine treatment for patients with delirium was effective and safe. This newer drug may be a useful alternative agent to classical antipsychotics in the treatment of delirium.
- 1 October 2001
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 55 (5) , 515-519
Open AccessAn open pilot trial of olanzapine for delirium in the Korean population
This study was performed to assess the efficacy and safety of olanzapine for the treatment of delirium in a Korean population. An open trial of olanzapine was conducted in Korean patients with delirium caused by multiple medicosurgical conditions. All subjects were evaluated by Delirium Rating Scale (DRS), which is known to be one of the most sensitive scales for delirium. In addition, other data for profiles of side‐effects were collected and analyzed. Twenty patients were treated by olanzapine with doses of 5.9 ± 1.5 mg/day. The initial dose was 4.6 ± 0.9 mg/day and maximal dose of olanzapine was 8.8 ± 2.2 mg/day. The average duration of treatment was 6.6 ± 1.7 days and the day of maximal response was 3.8 ± 1.7 treated days. The scores of DRS were significantly improved from 20.0 ± 3.6 at the time of pretreatment to 9.3 ± 4.6 at the post‐treatment. All subjects showed no definite serious side‐effects including anticholinergic and extrapyramidal symptoms. Olanzapine treatment for patients with delirium was effective and safe. This newer drug may be a useful alternative agent to classical antipsychotics in the treatment of delirium.